4Ei-10 interdiction of oncogenic cap-mediated translation as therapy for non-small cell lung cancer
- 23 November 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Investigational New Drugs
- Vol. 39 (3), 636-643
- https://doi.org/10.1007/s10637-020-01036-8
Abstract
Summary In order to suppress 5′ cap-mediated translation a highly available inhibitor of the interaction between the 5’ mRNA cap and the eIF4E complex has been developed. 4Ei-10 is a member of the class of ProTide compounds and has elevated membrane permeability and is a strong active chemical antagonist for eIF4E. Once taken up by cells it is converted by anchimeric activation of the lipophilic 2-(methylthio) ethyl protecting group and after that Hint1 P-N bond cleavage to N7-(p-chlorophenoxyethyl) guanosine 5′-monophosphate (7-Cl-Ph-Ethyl-GMP). Using this powerful interaction, it has been demonstrated that 4Ei-10 inhibits non-small cell lung cancer (NSCLC) cell growth. In addition, treatment of NSCLC cells with 4Ei-10 results in suppression of translation and diminished expression of a cohort of cellular proteins important to maintaining the malignant phenotype and resisting apoptosis such as Bcl-2, survivin, and ornithine decarboxylase (ODC). Finally, as a result of targeting the translation of anti-apoptotic proteins, NSCLC cells are synergized to be more sensitive to the existing anti-neoplastic treatment gemcitabine currently used in NSCLC therapy.Keywords
This publication has 48 references indexed in Scilit:
- Treatment of Breast and Lung Cancer Cells with a N-7 Benzyl Guanosine Monophosphate Tryptamine Phosphoramidate Pronucleotide (4Ei-1) Results in Chemosensitization to Gemcitabine and Induced eIF4E Proteasomal DegradationMolecular Pharmaceutics, 2013
- Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung cancerCancer Biology & Therapy, 2012
- Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4FProceedings of the National Academy of Sciences of the United States of America, 2010
- Targeting Eukaryotic Translation Initiation Factor 4E (eIF4E) in CancerClinical Cancer Research, 2010
- Activated 4E-BP1 represses tumourigenesis and IGF-I-mediated activation of the eIF4F complex in mesotheliomaBritish Journal of Cancer, 2009
- Inhibition of Ovarian Cancer Growth by a Tumor-Targeting Peptide That Binds Eukaryotic Translation Initiation Factor 4EClinical Cancer Research, 2009
- Regulation of Translation Initiation in Eukaryotes: Mechanisms and Biological TargetsCell, 2009
- Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicityJCI Insight, 2007
- Repression of Cap-Dependent Translation Attenuates the Transformed Phenotype in Non–Small Cell Lung Cancer Both In vitro and In vivoCancer Research, 2006
- Translation Initiation Factor 4E Blocks Endoplasmic Reticulum-mediated ApoptosisOnline Journal of Public Health Informatics, 2004